Background: Psychotropic drugs can induce an important (>5%) weight gain (WG) already
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INTRODUCTION
Overweight and obesity are major public health problems of the current decade, with a prevalence of obesity (body mass index (BMI)≥30kg/m 2 ) in the general population ranging from 20% to 23% in Europe (1) and reaching 35% in the US (2) . In the psychiatric population, an even higher prevalence of obesity is reported, reaching 49% and 55% for bipolar and schizophrenic patients, respectively (3) . In line with obesity-related problems, the psychiatric population have a quadrupled and doubled incidence of type 2 diabetes mellitus (T2DM) and hypertension, respectively, as compared to healthy controls (4) . This high prevalence of metabolic disorders can be explained, in addition to the effects of the psychiatric illness itself, by the use of psychotropic drugs such as most atypical and also some classical antipsychotics, mood stabilizers (e.g. valproate and lithium) and some antidepressants (e.g. mirtazapine) known to induce important weight gain (WG) (5, 6) . The exact mechanism of psychotropic-induced weight gain (PIWG) is only partially understood, although several clinical and individual factors have been shown to be associated, such as gender (women being at higher risk than men), low baseline BMI, young age, first episode or non-Caucasian ethnicities (5, (7) (8) (9) .
Genetic associations with BMI have been widely investigated in general as well as psychiatric populations. Currently, genome-wide association studies (GWAS) have highlighted 32 singlenucleotide polymorphism (SNPs) associated with BMI in cohorts of up to 240000 subjects (10) . However, despite the increasing number of SNPs discovered, the explained BMI variance in the general population remains low (1.45%) reflecting the complexity of mechanisms implicated in WG and the concomitant involvement of many environmental factors (10) . With regard to psychiatric patients, a high interindividual variability of PIWG is also observed and may be explained in part by genetic variability. Thus, PIWG was found to be heritable as shown in a study including siblings (11) . In addition, several SNPs were found to be associated with PIWG, suggesting that there are, similarly to the general population, many genetic contributions to WG. Because second generation antipsychotics interact with serotonin and dopamine systems, several candidate gene studies were conducted on SNPs located in serotonin HT 2C receptor, dopamine D 2 receptor or histamine H 1 receptor genes (12) .
Some discrepant results were published, which can be explained by methodological issues such as a lack of multiple testing correction, population stratification, insufficient sample size or inappropriate statistical analysis (13) . However, promising results were obtained for other genes (12, 14) which may contribute to the understanding of PIWG mechanisms. Indeed, SNPs located in CRTC1, PCK1, MCHR2, HSD11β1 genes were found to be associated with BMI and replicated in 3 psychiatric cohorts (14) (15) (16) (17) . Although some of these SNPs were significantly associated with BMI in general population-based cohorts, effect sizes were higher in psychiatric cohorts, suggesting an important interaction between gene and environmental factors (e.g. psychiatric illness, pharmacological treatment and lifestyle).
WG can be fast and may occur during the first month of treatment, underlining the importance of monitoring metabolic parameters directly when the drug is introduced and on a regular basis during treatment. Predictive calculations made during clinical trials have
shown that patients with a rapid WG during the first month of treatment are at a higher risk to have a more important WG on the long term (18) (19) (20) . Furthermore, we recently showed that a >5% WG during the first month of treatment is a good predictor for major WG at 3 (>15%) and 12 months (>20%), disregarding of the prescribed WG-inducing psychotropic drug (21) . However, detection of patients at high risk for early WG, even before the start of the psychotropic treatment, would be of high clinical relevance for a personalized prescription. In the present study, we sought to determine, in a psychiatric cohort with compliance ascertained by therapeutic drug monitoring, how clinical risk factors combined with an extensive analysis of genes previously identified to be associated with BMI using GWAS or candidate gene approaches, may allow to detect patients at risk for a>5% WG after one month of psychotropic drug treatment.
The obtained results were then tested for replication in a second independent psychiatric cohort.
METHODS

Patient selection:
Patients were selected from a previously published longitudinal observational study based on our clinical guideline requiring a metabolic follow-up after starting with or switching to clozapine, olanzapine, risperidone, quetiapine, aripiprazole, amisulpride, lithium, valproate and/or mirtazapine (22) . Detailed patient selection criteria were previously published (21) with the exception of the criteria mentioned below. Patients were included in the analysis only when compliance was confirmed by therapeutic drug monitoring at one month visit (or at three months if no plasma was available at one month (n=40)), with a minimal follow-up duration of one month and with Caucasian ethnicity. Patients were considered compliant when drug plasma concentrations were higher than 10 % of the lower value of the recommended therapeutic range (23) .
Because of the naturalistic design of the study, the one month visit could be performed at variable times but only data from patients with a visit between 15 and 45 days were retained. All clinical chemistry parameters were determined on plasma samples drawn in the morning in fasting conditions as previously published (21) .
Patients from the discovery cohort were included between 01.01.2007 and 08.04.2013.
Ethnicity was assessed by patient's reported ethnicity and confirmed by genotyping using principal component analysis with the EIGENSTRAT algorithm implemented in GCTA software (24) . The majority of the variance was explained by the two first vectors, and Caucasian ethnicity was arbitrarily selected when pca1<0.005 and pca2>-0.02, values which gave the highest concordance with the patient's reported ethnicity (see Figure No principal component analysis could be performed on these patients, thus ethnicity was based on patient's reported ethnicity.
The study was approved by the Ethics Committee of the Lausanne University Hospital and written informed consent for genetic analysis was obtained from all participants.
SNP selection and Genotyping:
23 SNPs significantly associated with T2DM (GWAS-T2DM; P<5 x 10 -8
) and 32 SNPs significantly associated with BMI (GWAS-BMI; P<5 x 10
), discovered by a GWAS approach in the general population samples were included (10, 25) . Finally 34 SNPs selected from a literature review investigating antipsychotic induced WG during the first three months of treatment were also included if published p-values were lower than 0.1 (see Table, Supplemental Digital Content 2).
Genomic DNA was extracted from EDTA blood samples with the FlexiGene DNA extraction kit (QIAGEN, Hombrechtikon, Switzerland) according to the manufacturer's protocol. All patients from the discovery cohort were genotyped on a MetaboChip array and processed on an iScan equipped platform (Illumina, San Diego, California). Only SNPs of interest (i.e, from genes previously identified to be associated with BMI and T2DM using GWAS or candidate gene approaches) were included in the present study. Quality control of investigated SNPs were assessed by the call rate (>96%), GenCall score (>0.15) and matched gender. SNPs were extracted from the database by using GenomeStudio software (version 2011.1, Illumina, San Diego, California).
Patients included in the replication cohort were genotyped by KBioscience Institute in United Kingdom using the fluorescence-based competitive allele-specific PCR technology (KASP™). about  this  technology  are  available  at: http://www.lgcgenomics.com/genotyping/kasp-genotyping-chemistry.
Details
Predictive models:
Logistic regression analyses were carried out to investigate the influence of the selected SNPs on early WG. In order to facilitate the understanding of the calculated odd-ratios, age, illness duration and baseline BMI were categorized by each 10 years (age/10, years/10 and BMI/10 respectively). Due to a small number and an unequal distribution (non-interventional study) 
Replication analysis
The statistical model developed on the discovery cohort was used to predict >5% WG. To compare the model performance, predictive statistics obtained in the replication cohort were compared to the previous model.
Evolution of weight over one year
To explore the evolution of WG over one year between patients with an observed or a predicted ≤5% WG and >5% WG, a Generalized Additive Mixed Model (GAMM) was fitted on the discovery and replication cohort combined together. To be more robust in inferences, a linear mixed effect model was also fitted on the same data, to reinforce the results of GAMM.
Observations made at one, two, three, six, nine and 12 months was used to fit the model.
Predictions made by the final model including both clinical and genetic variables were used to construct the grouping variable. The effect of time on weight gain was not considered as linear but was better represented by a smooth semi-parametric curve (with cubic regression spline basis). GAMMs were fitted separately for each sub-group (>5% WG and ≤5% WG) to
give the possibility of capturing the weight-gain trend without restraint at each sub-group (otherwise, a parallel trend in time would have been imposed on all sub-groups). These models were not adjusted for multiple comparisons, covariates or cofactors as they were used only to explore the data and the adequacy of the final model.
Afterwards, confirmatory analyses were made by fitting a linear mixed effect model ("nlme" package of R (30)) adjusted for age, sex, time, baseline BMI. The fitted linear mixed effect model (31) had a random effect at the subject level. To be more robust in inferences, a bootstrap analysis (32) was used to evaluate the uncertainty of estimated parameters (evaluated uncertainties are more conservative, but more reliable if there are violations from model assumptions, as normality assumption for residuals). Results were based on 10000 bootstrap replicates at the subject level (subjects were considered to be independently recruited) and increasing the number of bootstraps did not influence substantially the uncertainty of estimated parameters.
Evaluation of benefit of pharmacogenetic screening
The number needed to genotype (NNG), defined as the number of patients to genotype in order to detect one misclassified case by using only clinical information was determined (33).
The calculation methodis based on the inverse of the difference between the accuracy of the model including both clinical and genetic data and the accuracy of the model including clinical data only.
All tests were two sided and p-values ≤0.05 were considered as statistically significant. All statistical analyses were carried out using R software (version 2.15.2).
RESULTS
Demographics of the discovery cohort:
248 patients were included (see Figure, Supplemental were less frequent in the ≤5% WG than in the >5% WG patients (60% vs 79%, p=0.01).
Abdominal obesity and hypo HDL-cholesterolemia were more prevalent in the ≤5% WG Table 1 .
Genotyping results:
Proxy (r 2 >0.75) were searched for 20 SNPs that were not available in the MetaboChip (for each missing SNP a proxy was found). Two SNPs from GWAS-T2DM, one SNP from the GWAS-BMI and three SNPs from the gene candidate studies deviated from Hardy-Weinberg equilibrium and were excluded from further analysis (see Table, Supplemental Digital Content 2, which are presented in bold). The minor allele frequencies ranged from 3% to 49% and were in agreement with the 1000 Genome Project Phase 1 (data not shown).
Multivariate analysis and prediction model:
Clinical model:
Low baseline BMI was a significant risk factors for >5% WG. No significant associations were observed between age, illness duration, polymedication, gender and the type of newly prescribed psychotropic drug and >5% WG at one month (table 2, left column).
Genetic models:
GWAS-Type 2 diabetes mellitus SNPs:
Four of the 21 SNPs were retained after AIC selection. None of the selected SNPs were significantly associated with WG at one month (see Table, Supplemental Digital Content 4).
As presented in table 3, inclusion of these 4 SNPs did not increase accuracy and AUC.
GWAS-BMI SNPs:
Model based on AIC retained 12 SNPs of the initial set of 31 SNPs. The three most significant SNPs were ZNF608 rs6864049; GPRC5B, IQCK rs12444979 and TMEM160, ZC3H4 rs3810291 (see Table, 
Candidate gene SNPs:
31 SNPs from candidate gene studies were included in the logistic model. After AIC selection, 9 SNPs were retained. The 3 most significant SNPs were ADIPOQ rs17300539, INSIG2 rs17587100 and FAAH rs324420 (see Table, NPV and PPV was also observed (Table 3 ). An increase of predicted risk, as shown in figure 1 (left), was observed for 46 patients having a >5% WG (red dots) and 45 patients having ≤5%
WG (green dots) whereas 10 patients with >5% WG and 147 patients with ≤5% WG have a decrease of their predicted risk after inclusion of genetic data. Distribution of predicted risk (figure1, right), indicates that 80% of ≤5% WG patients (gray bar) have a less than 20% predicted risk to have a >5% WG.
Replication cohort
A small sample of 32 newly included patients with compliance ascertained was used as replication cohort. These patients were significantly younger than in the discovery cohort (median (IQR) age: 33 (20) versus 46(41) years old, p=0.02). No other differences were observed between the two cohorts except for aripiprazole, lithium and olanzapine which were more prescribed in the replication cohort and risperidone which was more prescribed in the discovery cohort (see Table, Supplemental Digital Content 8). Comedication possibly inducing WG was also more frequent in the discovery cohort.
The discovery model was used to predict >5% WG for the 32 patients in the replication cohort (see Table, p AUC =0.9). Accuracy, specificity, sensitivity, NPV and PPV layed outside of the 95 th interval (Table 3) which may be explained, in part, by the small size of the replication cohort. There was no difference as to the predicted risk between the two cohorts when comparing patients with ≤5% WG (p=0.2) and >5% WG (p=0.1, see Figure, Supplemental Digital Content 11).
Validation for long term weight changes:
GAMM prediction of WG over the first year is represented in figure 2 (see Figure, Supplemental Digital Content 12, which presents raw data). Patients having >5% WG after one month of treatment (left plot, red line) had a stronger WG during the first year of treatment than patients having ≤5% WG (green line; linear mixed model controlled by several confounders: β=7.8%; p adjusted <0.0001; see Table, Supplemental Digital Content 13).
Patients predicted before treatment to have >5% or ≤5% WG after one month of treatment, based on clinical and genetic data, are shown on the right plot (figure 2).The difference of WG between the two predicted groups was significant after one year (β=4.4%; p adjusted <0.0001; see Table, Supplemental Digital Content 13).
Number needed to genotype
Accuracy (i.e. percentage of correctly classified cases) increased by 17% (from 70% to 87%) with the final model including clinical and genetic data as compared to the clinical model alone. In other words, 6 patients have to be genotyped to detect one patient misclassified after using clinical parameters only.
DISCUSSION
A fast (after one month) and important (>5%) WG following treatment with WG inducing psychotropic drugs has been shown to be a good predictor for important long term weight changes (21) , highlighting the need to regularly monitor WG during psychotropic treatment (3, 22) . Thus, detection of patients at risk even before starting the treatment could be useful for a personalized prescription, to minimize PIWG and long term metabolic consequences.
Several clinical variables such as young age, low BMI or female gender are known risk factors for PIWG (34). In the present study, we showed that a combination of genetic data resulting from an extensive genetic analysis of patients in addition to clinical risk factors could improve the ability to detect patients at increased risk before starting a pharmacological treatment with WG inducing psychotropic drugs. We confirmed that baseline BMI and age were significantly associated with a >5% WG (table 2, right column), underlining the vulnerability of young patients (children and adolescents) to PIWG (7, 9, 35) . No significant influence of medication, neither analyzed separately (data not shown) nor clustered in function of their potential weight gain magnitude (amisulpride, aripiprazole vs risperidone, quetiapine, mirtazapine, lithium vs clozapine, olanzapine, and valproate), was observed in the multivariate analysis. This could be explained by the combined effect of present and past treatment as most patients were not drug naïve. However, a higher proportion of olanzapine prescription was observed in the >5% WG group, in agreement with the fact that olanzapine is one of the most potent WG inducing antipsychotic.
The model combining clinical and genetic data selected from T2DM-GWAS showed no significant AUC increase compared to the clinical model alone. This could first be explained by the short duration of treatment examined in the present study, which diminishes the possible influence of genes associated with diabetes. In addition, T2DM is likely to involve essentially different genes, with different biological pathways than WG. This conclusion is supported by a review concluding that there is, to date, a limited shared genetic aetiology between type 2 diabetes and obesity (36).
In addition to clinical data, the final model contains 18 SNPs from candidate gene studies investigating PIWG during the first 3 months of treatment and from a GWAS investigating BMI in general populations. Although several SNPs were not individually significantly associated with BMI, retaining them in the final model using AIC selection significantly improved the fit, suggesting gene-gene interactions. Considering genetic variants which were most significantly associated with fast and important WG, ADIPOQ rs17300539, located in the promoter region, was found to be strongly associated with low adiponectin levels (37). It could thus be associated with metabolic disorders, although discrepant results have been published intwo meta-analyses investigating obesity and T2DM (38, 39). The FAAH rs324420
SNP is located in the fatty acid amide hydrolase locus, and the present result is in agreement with a study investigating PIWG (40). Of note, beside associations with metabolic traits, FAAH belongs to the endocannabinoid system and was also related to several psychiatric disorders (41, 42) underlying possible common risk factors between psychiatric and metabolic disorders. The same remark also applies to GPRC5B, IQCK rs12444979 which was found to be associated with attention-deficit/hyperactivity disorder and BMI (43).
Adding SNPs selected from GWAS investigating BMI (10) have an important WG over the first year of treatment compared to the patients predicted as not being at risk for 5%WG, underlining the importance of an early WG and the 5% threshold for predicting long term weight changes (21) .
Several limitations of the present study need to be acknowledged. Firstly, most of the patients were not drug naïve, and thus possibly already experienced major WG during previous pharmacological treatments. However, non-drug naïve psychiatric patients represent the majority of cases in clinical practice, which should strengthen the validity of our results in real world conditions. Secondly, although the choice of genes included in the present study is already extensive, it is almost certain that other genes will be discovered in the future to be associated with PIWG, in particular by using exome or whole genome sequencing. However, the present model already reaches 87% accuracy, and although it can be increased, 100% accuracy will most probably never be reached even after adding more The strengths of the present study include its naturalistic setting, a longitudinal design with weight having been monitored at introduction and after regular time intervals. Moreover, therapeutic drug monitoring was used to assess compliance, which is an important issue in psychiatry. Indeed major WG is a strong risk factor for poor or non-compliance, possibly leading to false evaluation of the patients (no WG because of non-compliance). To our knowledge, the present study is the most thorough genetic study performed in psychiatric patients for predicting WG during psychotropic treatment with the validity of the model confirmed in a replication cohort.
In conclusion, this study explores the potential role of known SNPs to identify subjects at risk of a rapid WG during the first month of treatment, which is an important issue for long term MAF-caucasian population (%) th percentiles for each parameter were determined by using 10000 bootstraps. b P-value were calculated between the AUC of the model containing clinical data and the model containing clinical and genetic data. 2000 bootstraps were used for the analysis. c Due to too small sample size, no bootstrap could be performed and thus no percentiles were obtained.
In bold are the parameters lying out of the corresponding 95 th calculated in the clinical model, which is considered as different.
Abbreviations: TN=True negative (n cases); TP=True positive (n cases); FN=False negative (n cases); FP=False positive (n cases); SP=Specificity; SE=Sensibility; NPV=Negative predictive value; PPV=positive predictive value; AUC=Area under the curve.
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Logistic regression results including SNPs related to BMI 
